Bioventus (BVS) Short-term Investments (2021 - 2022)
Bioventus' (BVS) quarterly Short-term Investments came in at $23000.0 in Q4 2022, down 99.56% on a YoY basis from $5.3 million in Q4 2021, and little changed quarter-over-quarter from $23000.0 in Q4 2022.
Powered by 
Analysis
Bioventus (BVS) Short-term Investments (2021 - 2022) Analysis & Trends
Bioventus (BVS) has reported Short-term Investments for 2 consecutive years, with $23000.0 the latest figure, recorded in Q4 2022.
- For the quarter ending Q4 2022, Short-term Investments fell 99.56% year-over-year to $23000.0; the trailing twelve-month figure through Dec 2022 stood at $23000.0 (down 99.56% YoY), and the FY2022 full-year result was $23000.0, down 99.56% from the prior year.
- Short-term Investments steadied at $23000.0 in Q4 2022 per BVS's latest filing, from $23000.0 in the prior quarter.
- Across five years, Short-term Investments topped out at $5.3 million in Q4 2021 and bottomed at $23000.0 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn |
| 10 | Bioventus | 923.70 Mn | 894.24 Mn | 105.67 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 23,000.00 |
| Oct 1, 2022 | 23,000.00 |
| Apr 2, 2022 | 5.28 Mn |
| Dec 31, 2021 | 5.28 Mn |
| Jul 3, 2021 | 2.00 Mn |
| Apr 3, 2021 | 5.21 Mn |